Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy

Gene Therapy volume 12, pages 187–193 (2005)Cite this article

Abstract

Adenoviruses (Ads) are efficient gene transfer vehicles, but Ad-mediated gene therapy for ovarian cancer remains limited in vivo by inefficient and nonspecific gene transfer. Mesothelin (MSLN), a cell surface glycoprotein, is overexpressed in ovarian cancer but not in normal tissues except mesothelial cells. Therefore, MSLN is an attractive candidate for transcriptional and transductional targeting in the context of ovarian cancer gene therapy. We evaluated the expression of MSLN mRNA and MSLN surface protein in ovarian cancer cells. Ads containing the MSLN promoter driving reporter gene expression were created and tested in ovarian cancer cell lines and purified ovarian cancer cells isolated from patients. To evaluate transductional targeting, we used an Ad vector containing an Fc-binding domain within the fiber protein, which served as a docking domain for binding with anti-MSLN immunoglobulins. Both RT-PCR and flow cytometry revealed high MSLN gene and protein expression in ovarian cancer cells. The MSLN promoter was activated in ovarian cancer cells, but showed significantly reduced activity in normal control cells. Transductional targeting of Ads via anti-MSLN antibody increased transgene expression in ovarian cancer cells. This report describes the use of MSLN for transcriptional as well as transductional targeting strategies for ovarian cancer gene therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Jemal A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26.

    Article  PubMed  Google Scholar 

  2. Hallenbeck PL et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721–1733.

    Article  CAS  PubMed  Google Scholar 

  3. Chang K, Pastan I . Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996; 93: 136–140.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Chang K, Pastan I . Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. Int J Cancer 1994; 57: 90–97.

    Article  CAS  PubMed  Google Scholar 

  5. Urwin D, Lake RA . Structure of the mesothelin/MPF gene and characterization of its promoter. Mol Cell Biol Res Commun 2000; 3: 26–32.

    Article  CAS  PubMed  Google Scholar 

  6. Hassan R et al. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res 2002; 8: 3520–3526.

    CAS  PubMed  Google Scholar 

  7. Frierson Jr HF et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003; 34: 605–609.

    Article  CAS  PubMed  Google Scholar 

  8. Barker SD et al. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol Oncol 2001; 82: 57–63.

    Article  CAS  PubMed  Google Scholar 

  9. Schaner ME et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003; 14: 4376–4386.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Casado E et al. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res 2001; 7: 2496–2504.

    CAS  PubMed  Google Scholar 

  11. Hemminki A et al. Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res 2001; 61: 6377–6381.

    CAS  PubMed  Google Scholar 

  12. Fan D et al. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol Cancer Ther 2002; 1: 595–600.

    Article  CAS  PubMed  Google Scholar 

  13. Brinkmann U et al. Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers. Int J Cancer 1997; 71: 638–644.

    Article  CAS  PubMed  Google Scholar 

  14. Reynolds PN et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 2001; 19: 838–842.

    Article  CAS  PubMed  Google Scholar 

  15. Vile RG, Sunassee K, Diaz RM . Strategies for achieving multiple layers of selectivity in gene therapy. Mol Med Today 1998; 4: 84–92.

    Article  CAS  PubMed  Google Scholar 

  16. Barker SD et al. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Therapy 2003; 10: 1198–1204.

    Article  CAS  PubMed  Google Scholar 

  17. Barnett BG, Tillman BW, Curiel DT, Douglas JT . Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells. Mol Ther 2002; 6: 377–385.

    Article  CAS  PubMed  Google Scholar 

  18. Lam JT et al. Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Ther 2003; 10: 377–387.

    Article  CAS  PubMed  Google Scholar 

  19. Kanerva A et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275–280.

    CAS  PubMed  Google Scholar 

  20. Danilov SM et al. Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. Am J Physiol Lung Cell Mol Physiol 2001; 280: L1335–L1347.

    Article  CAS  PubMed  Google Scholar 

  21. Korokhov N et al. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol 2003; 77: 12931–12940.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by Grant D/02/33141 of the Dr Mildred Scheel Stiftung für Krebsforschung, and the NIH (R01 HL67962, P50 CA89019, R01 CA86881, R01 AG021875, R01 CA090547). The Mesothelioma Applied Research Foundation, Inc.

Author information

Authors and Affiliations

  1. Division of Human Gene Therapy, Departments of Medicine, Surgery, Pathology and the Gene Therapy Center, Birmingham, AL, USA

    M Breidenbach, D T Rein, M Everts, M Wang, M J Passineau & D T Curiel

  2. VectorLogics, Inc, Birmingham, AL, USA

    J N Glasgow & N Korokhov

  3. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL, USA

    R D Alvarez

  4. Department of Obstetrics and Gynecology, Rhine-Westphalian Technical University (RWTH), Aachen, Germany

    M Breidenbach

Authors
  1. M Breidenbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D T Rein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Everts
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J N Glasgow
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M J Passineau
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R D Alvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N Korokhov
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D T Curiel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Breidenbach, M., Rein, D., Everts, M. et al. Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther 12, 187–193 (2005). https://doi.org/10.1038/sj.gt.3302404

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302404

Keywords

This article is cited by

Search

Advanced search

Quick links